臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 871-895 / 1656 (共67頁)
<< < 30 31 32 33 34 35 36 37 38 39 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-04-10T12:51:17Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:16Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:16Z	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Hsu C.-H.; Hu F.-C.; Hsu C.-Y. ;Shen Y.-C. ;Yu C.-W. ;Chiun Hsu ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Chiun Hsu; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2020-04-10T12:51:15Z	Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials	Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Chiun Hsu; Hsu C.-H.; Kuo S.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:15Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y.
臺大學術典藏	2020-04-10T12:51:14Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Lin Z.-Z.; Chiun Hsu; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2020-04-10T12:51:13Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:13Z	Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer	Cheng A.-L.; Yeh K.-H.; Chiun Hsu; Cheng W.-F.; Lin Y.-L.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.
臺大學術典藏	2020-04-10T12:51:11Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lin Z.-Z.
臺大學術典藏	2020-04-10T12:51:11Z	Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study	Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.
臺大學術典藏	2020-04-10T12:51:10Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2020-04-10T12:51:04Z	Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy	Shih T.T.-F.; Cheng A.-L.; Hsu C.-H.; Chiun Hsu; Liang P.-C.; Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W.
臺大學術典藏	2020-04-10T12:51:03Z	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer	Yang S.-H.;Kuo T.-C.;Wu H.;Guo J.-C.;Chiun Hsu;Hsu C.-H.;Tien Y.-W.;Yeh K.-H.;Cheng A.-L.;Kuo S.-H.; Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Chiun Hsu; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2020-04-10T12:51:03Z	Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges	Lu L.-C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.
臺大學術典藏	2020-04-10T12:51:01Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu
臺大學術典藏	2020-04-10T12:51:01Z	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma	Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Chiun Hsu; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2020-04-10T12:16:14Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Cheng A.-L.; Hsu C.; Ding Y.-H.; YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H.
臺大學術典藏	2020-04-10T12:16:13Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:16:12Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:16:12Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	YU-YUN SHAO; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:16:12Z	Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy	YU-YUN SHAO; Lu L.-C.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2020-04-10T12:16:12Z	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma	YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:16:11Z	Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma	Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2020-04-10T12:16:10Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2020-04-10T12:16:10Z	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma	Cheng A.-L.; YU-YUN SHAO; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H.

顯示項目 871-895 / 1656 (共67頁)
<< < 30 31 32 33 34 35 36 37 38 39 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52712656 線上人數 : 556 教育部委託研究計畫計畫執行:國立臺灣大學圖書館